The new TRT program and brand identity marks the next chapter for the company that has treated more than 400,000 patients with its performance-driven health solutions AUSTIN, Texas, March 10, ...

Dr. Raza Bokhari, Executive Chairman & CEO will participate in panel discussions and highlight Company's AI-enabled Drug Development Strategy PHILADELPHIA, PA / ACCESS Newswire / March 10, 2026 / ...

I'm a 53-year-old woman and I recently lost my libido overnight. I woke up and it had gone. I used to have a very good sex life, though I do get some vaginal pain during and after sex. What has ...

Sifting through countless of stocks in the Biotechnology industry can be tedious, and sometimes two stocks are just too similar to judge which is the better investment. If you’re on the fence about ...

After one of El Paso’s only pediatric endocrinologists was accused of illegally providing gender-transitioning treatments to kids, his patients who aren’t transgender lost care.

SALT LAKE CITY, March 10, 2026 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its proprietary technology platform to augment therapeutics through effective oral ...

Amid an explosion of aging research, there are plenty of “biohackers” out there jumping the gun without waiting for proof of efficacy.

Atlanta Braves manager Walt Weiss comments again on Jurickson Profar’s PED suspension following the outfielder’s second ...

Despite their persistent health struggles, they leave the doctor’s office with a simple “everything looks fine” after routine tests. However, feeling “off” is not something to dismiss. THRIVE Health & ...

NHS England has “paused” the prescribing of gender affirming hormones to treat gender incongruence or dysphoria for young people under 18. The health service said that it came to this decision after a ...

Hims & Hers is downgraded to hold as the 40% rally after Novo Nordisk’s dismissal of its lawsuit is likely driven by a short ...

The largest cardiovascular outcomes trial on TRT ever conducted changed the clinical conversation — but most men ...